Printer Friendly

Immune Pharmaceuticals names G. John Mohr as SVP of business development.

M2 PHARMA-December 8, 2015-Immune Pharmaceuticals names G. John Mohr as SVP of business development


Novel therapies company Immune Pharmaceuticals (NasdaqCM:IMNP) reported on Monday the election of G. John Mohr as senior vice president of its business development as well as a member of its executive committee.

In the new position, Mohr will lead and be responsible for overseeing alliance and business development activities for the company.

Most recently, Mohr has served as the managing director at BioAsset Advisors advising public and private companies on strategic partnering and licensing activities.

Previously, Mohr has worked as the senior vice president at CV Therapeutics, chief operating officer at Topigen Pharmaceuticals, senior vice president at Atherogenics as well as president at Fournier Pharma US.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 8, 2015
Previous Article:Adamis Pharmaceuticals resubmits Epinephrine Pre-Filled Syringe's NDA to the US FDA.
Next Article:Onconova treats first HR-MDS patient in Phase 3 INSPIRE Trial of Rigosertib at MD Anderson Cancer Centre.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters